Drugs / Autologous adipose-derived mesenchymal stem cells
Autologous adipose-derived mesenchymal stem cells
also known as
JointStem · AD-MSCs · ATCell · Autologous Adipose Tissue derived MSCs · AD-MSC · autologous adipose tissue-derived mesenchymal stem cell · MSC
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05018871 | Dec 2025 → Dec 2028 | cerebral palsy | The Foundation for Orthopaedics and Regenerative Medicine | Suspended | No outcome recorded |
| Phase 1 | NCT05018793 | Dec 2024 → Dec 2028 expected | spinal cord injury | The Foundation for Orthopaedics and Regenerative Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05669261 | Aug → Dec 2023 | long COVID-19 | American CryoStem Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT03308565 | Dec 2017 → Oct 2019 | palsy, spinal cord injury | Mohamad Bydon | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06726538 | Oct 2023 → Dec 2025 | sexual disorder | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT04426643 | Aug 2020 → Feb 2021 | — | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Completed | No outcome recorded |
| Phase 1/2 | NCT05827757 | Apr 2020 → Apr 2025 | — | DNA International Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04446884 | Mar 2018 → Dec 2019 | female stress incontinence | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Completed | No outcome recorded |
| Phase 1/2 | NCT01649700 | Oct 2011 → May 2013 | brain injury | National Yang Ming Chiao Tung University | Completed | No outcome recorded |
| Phase 1/2 | NCT04457037 | Oct 2009 → Dec 2013 | chronic ulcer of skin | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04520373 | Jun 2020 → Jul 2026 overdue | palsy, spinal cord injury | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03509025 | Feb 2017 → Dec 2020 | osteoarthritis, knee | R-Bio | Completed | No outcome recorded |
| Phase 2 | NCT02674399 | Feb 2016 → Mar 2018 | osteoarthritis, knee | Nature Cell Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02658344 | Jul 2015 → Nov 2016 | osteoarthritis, knee | R-Bio | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04368806 | May 2021 → Dec 2026 expected | osteoarthritis, knee | Nature Cell Co. Ltd. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04427930 | Apr 2020 → Dec 2026 expected | osteoarthritis, knee | R-Bio | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03990805 | Jun 2019 → Dec 2020 | osteoarthritis, knee | R-Bio | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT04825730 | Dec 2023 → Dec 2028 expected | osteoarthritis, knee | R-Bio | Not yet recruiting | No outcome recorded |
| — | NCT04821102 | Jul 2023 → Aug 2024 | osteoarthritis, knee | R-Bio | Unknown | No outcome recorded |
| — | NCT03956719 | Mar 2019 → Sep 2020 | osteoarthritis, knee | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| — | NCT03000712 | Nov 2016 → May 2020 | osteoarthritis, knee | R-Bio | Completed | No outcome recorded |
| — | NCT02474342 | Jul 2015 → Nov 2016 | rotator cuff syndrome | Seoul National University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04744051 Comparator | Feb 2021 → Sep 2023 | traumatic encephalopathy | American CryoStem Corporation | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01257776 Comparator | Dec 2010 → Feb 2013 | diabetes mellitus, limb ischemia | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous adipose-derived mesenchymal stem cells | “Transplant 100 million autologous adipose-derived mesenchymal stem cells at Day 0 and Day 90” NCT05827757 ↗ |
| Known as | AD-MSC | “autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation” PMID 38715140 ↗ May 2024 |
| Known as | AD-MSCs | “Adipose-derived mesenchymal stem cells (AD-MSCs) have been used in previous research studies at the Mayo Clinic.” NCT03308565 ↗3“patients treated with 2 infusions (100 million cells i.v) of autologous AD-MSCs were initially evaluated” PMID 38715140 ↗ May 2024 “cultured autologous adult adipose derived mesenchymal stem cells (AD-MSCs)” NCT05018793 ↗ “cultured autologous adult adipose derived mesenchymal stem cells (AD-MSCs)” NCT05018871 ↗ |
| Known as | ATCell | “The proposed study is a single-site, double-blinded, placebo-controlled study involving a single administration of either individual, autologous ATCell™ lines suspended in 5%...” NCT04744051 ↗ |
| Known as | Autologous Adipose Tissue derived MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03000712 ↗ |
| Known as | autologous adipose tissue-derived mesenchymal stem cell | “autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation” PMID 38715140 ↗ May 2024 |
| Known as | JointStem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02674399 ↗ |
| Known as | MSC | “autologous adipose-derived mesenchymal stem cell (MSC) therapy” NCT06726538 ↗ |
| Modality | Cell therapy | “treated with mesenchymal cells of adipose tissue” NCT01257776 ↗ |
| Route | Other | “Intra-arterial administration through a selective cannulation of target common femoral artery” NCT01257776 ↗ |